Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4150403 | 1.00 | USP2 (0.57) | USP2KDM4EALDH1A1ANPEPHSD17B10 | |
| Acrylic Acid SCHEMBL31047105 | 0.88 | USP2 (0.46) | USP2KDM4EALDH1A1ANPEPHSD17B10 | |
| SCHEMBL7288389 | 0.82 | ANPEP (0.56) | USP2KDM4EALDH1A1ANPEPHSD17B10 | |
| SCHEMBL31757733 | 0.82 | ALDH1A1 (0.61) | USP2KDM4EALDH1A1ANPEPHSD17B10 | |
| SCHEMBL5254183 | 0.81 | MEN1 (0.50) | ALDH1A1ANPEPHSD17B10MEN1KMT2A | |
| SCHEMBL5243859 | 0.81 | MEN1 (0.50) | ALDH1A1ANPEPHSD17B10MEN1KMT2A | |
| SCHEMBL5243190 | 0.79 | MEN1 (0.54) | ALDH1A1ANPEPHSD17B10MEN1KMT2A | |
| SCHEMBL19532370 | 0.79 | MEN1 (0.54) | ALDH1A1ANPEPHSD17B10MEN1KMT2A | |
| SCHEMBL7979638 | 0.78 | ALDH1A1 (0.68) | USP2KDM4EALDH1A1ANPEPHSD17B10 | |
| SCHEMBL27876610 | 0.78 | USP2 (0.55) | USP2KDM4EALDH1A1ANPEPHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582756-B2 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors | SUGEN, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1562600-A4 | COMBINATION ADMINISTRATION OF AN INDOLINONE WITH A CHEMOTHERAPEUTIC AGENT FOR CELL PROLIFERATION DISORDERS | SUGEN INC (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20080045709-A1 | 3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | SUGEN, INC. | 2008-02-21 | — | — | US | disclosed |
| EP-1446117-A4 | TREATMENT OF ACUTE MYELOID LEUKEMIA WITH INDOLINONE COMPOUNDS | SUGEN INC (US) | 2008-01-23 | — | — | EP | disclosed |
| US-7256189-B2 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors | SUGEN, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| US-7179910-B2 | 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-20070027149-A1 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors | SUGEN, INC. | 2007-02-01 | — | — | US | disclosed |
| EP-1599207-A2 | TREATMENT OF EXCESSIVE OSTEOLYISIS WITH INDOLINONE COMPOUNDS | Sugen, Inc. (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-1370554-B1 | 3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PHARMACIA & UPJOHN CO LLC (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-1562600-A2 | COMBINATION ADMINISTRATION OF AN INDOLINONE WITH A CHEMOTHERAPEUTIC AGENT FOR CELL PROLIFERATION DISORDERS | Sugen, Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040209937-A1 | Treatment of excessive osteolysis with indolinone compounds | SUGEN, INC. | 2004-10-21 | — | — | US | disclosed |
| WO-2004075775-A2 | TREATMENT OF EXCESSIVE OSTEOLYISIS WITH INDOLINONE COMPOUNDS | SUGEN, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
| EP-1446117-A2 | TREATMENT OF ACUTE MYELOID LEUKEMIA WITH INDOLINONE COMPOUNDS | Sugen, Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| WO-2004045523-A2 | COMBINATION ADMINISTRATION OF AN INDOLINONE WITH A CHEMOTHERAPEUTIC AGENT FOR CELL PROLIFERATION DISORDERS | SUGEN, INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| US-20040102510-A1 | 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors | SUGEN, INC. | 2004-05-27 | — | — | US | disclosed |
| US-6653308-B2 | Anticancer agents; antidiabetic agents; antiinflammatory agents | SUGEN, INC. | 2003-11-25 | — | — | US | disclosed |
| US-20030092917-A1 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as portein kinase inhibitors | SUGEN, INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2003035009-A2 | TREATMENT OF ACUTE MYELOID LEUKEMIA WITH INDOLINONE COMPOUNDS | SUGEN, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045709-A1 | 3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MAP4K2, MAP4K3, CDK2 | USP2 2330/4885KDM4E 884/4885ALDH1A1 3371/4885 |
| US-20040102510-A1 | 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors | MAP3K15, MAP3K19, MAP3K9 | USP2 3056/4885KDM4E 739/4885ALDH1A1 3240/4885 |
| US-20030092917-A1 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as portein kinase inhibitors | PDPK1, MKNK1, PKN2 | USP2 3652/4885KDM4E 1391/4885ALDH1A1 2945/4885 |
| US-20070027149-A1 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors | PDPK1, MAP4K2, MAP4K3 | USP2 2777/4885KDM4E 1154/4885ALDH1A1 2996/4885 |
| US-20040209937-A1 | Treatment of excessive osteolysis with indolinone compounds | CSF1R, CSF3R, CMKLR1 | USP2 4153/4885KDM4E 1941/4885ALDH1A1 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.